Telo Genomics Corp. is a molecular diagnostics company, which engages in the development of telomere analysis platforms in the industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. Its technologies utilize a multi-step process that involves capturing sample cells from blood or tissue, labeling, 3D formatting, processing and analyzing with TeloView. Its technologies are based on single cell biology. TeloView is a software platform, which is used to quantify specific features of each patient’s telomeres. The company quantifies six specific biological and structural features of telomeres and builds a score for each patient to assess their risk of disease progression and potential treatment response. TeloView helps in capturing the heterogeneity and complexity of cancers with relatively small sample sizes in clinical studies. Its initial lead includes multiple myeloma, prostate cancer and Alzheimer's disease.
TDSGF stock price ended at $0.03 on 星期四, after rising 0.00%
On the latest trading day Feb 12, 2026, the stock price of TDSGF rose by 0.00%, climbing from $0.03 to $0.03. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.03 and a high of $0.03. Alongside this price increase, trading volume also rose by 1.2K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 700 shares were traded, amounting to a market value of approximately --.